GBT may benefit from Bluebird potential safety concerns, says Piper Jaffray

Piper Jaffray analyst Danielle Brill notes that while the major catalyst for Global Blood Therapeutics (GBT) remains the regulatory update for voxelotor now expected tomorrow morning, she thinks the stock will also benefit from Bluebird Bio’s (BLUE) setback with its LentiGlobin gene therapy for SCD, namely a patient that developed MDS 3 years post LentiGlobin treatment. Global Blood Therapeutics and Bluebird Bio are two of the major players in the SCD space and Brill thinks patients and docs will prefer the former’s voxelotor “now more than ever,” given the potential safety liabilities of gene therapy. The analyst reiterates an Overweight rating and $80 price target on Global Blood’s shares.

https://thefly.com/landingPageNews.php?id=2830838